5023184 Antibiotics from myxococcus
1
676 I'A lENT ABSTRA( rs vironment for the entrapped test cells. ]'est cells are subjected to treatment either betbre or after incorporation into spheroids, and the eff'cct of such treatment is then evaluated from the colon 3 forming abilit3 of spheroids containing test cells. oligonuclcotidc sequence can he deri~,cd from the organism's ribonucleic or deoxyribonucleic acid that codes for a vital protcin, and can be synthesized in bulk either chemically or b~ inser- tion into a plasmid 5023184 ANTIBIOTICS FROM MYXOCOCCUS Hans Rcichenbach, Klaus Gerth, Herbert lr- ~hik, Brigittc Kunze. Gerhard Hofle, Hermann Augustiniak. Norbert Bedorf, RolfJansen, Wol- fram Trowitzseh-Kienast, Hcinrich Steinmetz, Wolfenb Federal Republic Of Germana as- signed to Ciba-Geigy Corporation; Gesellschaft fur giotechnologische Forschung m The invention relates to novel polycyclic alkaloids of formula See Patent /or Chemical Structure (I) in which R I represents hydrogen or hydroxy, R2 represents hydrogen or acyl and A and B. independently of one another, each represents C double bondO or C-OH, and wherein the dashed line represents a C double bond(." double bond at the position of the middle bond when A or B represents C double bondO, or at the position of the two outer bonds when A or B represents (;-OH, a process for the manu- facture of these compounds by fermentation of a novel microorganism of the species Myxococcus xanthus, the novel microorganism itself, pharmacetical preparations that contain the novel compounds, and the use of the novel com- pounds as antibiotics and as turnout-inhibiting agents and for the manufacture of pharma- ceutical preparations. 5023243 OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHOD OF MAKING SAME Richard H Tullis assigned to Molecular Bio- systems Inc For use in controlling biologic functions in an organism, a stabilized oligonucleotide, pre- ferably in a phosphotriester form, having a base sequence substantially complementary to a por- tion of messenger ribonucleic acid coding for a biological component, such as a protein, of the organism. The oligonucleotide has about four- teen bases or more, such as twenty-three bases, and can be a deoxyribonculeotide. The 5023320 PROCESS FOR THE PURIFICATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCE HAVING ANTITUMOR ACTIVITY Katsuyuk Haranaka, Lloyd J Old, Elizabeth Richards, Barbara Williamson. Knkubunji. NY. Japan assigned to Sloan-Kettering Institute For Cancer Research A process is provided for the purification of a proteinaceous physiologically active substance having antitumor activity, which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloen- dothelial system and then injecting endotroxin from a Gram-negative bacterium into the rabbit. The process comprises contacting a crude solu- tion of said proteinaceous physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, eluting the adsorbed physiologically active substance, and subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight in the range of 30,000 to 70,000. The purified preparation of said physiologically ac- tive substance thus obtained may be used as an antitumore agent for the treatment of malignant tumors. Said physiologically active substance is isolated by subjecting the purified preparation successively to affinity chromatography on im- mobilized Cibarcron Blue F3G-A. gel filtration. affinity chromatography on immobilized con- canavalin A, preparative electrophoresis on polyacrylamide gel and gel filtration. 5034133 PURIFICATION OF HUMAN INTERLEUKIN-4 FROM A CHO- CELl. LINE CULTURE MEDIUM David Naveh, Jay Raman, John C Tang, Leiden, N J, Netherlands assigned to Schering- Corporation
Transcript of 5023184 Antibiotics from myxococcus
676 I'A lENT ABSTRA( rs
vironment for the entrapped test cells. ]'est cells are subjected to treatment either betbre or after incorporation into spheroids, and the eff'cct of such treatment is then evaluated from the colon 3 forming abilit3 of spheroids containing test cells.
oligonuclcotidc sequence can he deri~,cd from the organism's ribonucleic or deoxyribonucleic acid that codes for a vital protcin, and can be synthesized in bulk either chemically or b~ inser- tion into a plasmid
5023184
A N T I B I O T I C S F R O M M Y X O C O C C U S
Hans Rcichenbach, Klaus Gerth, Herbert lr- ~hik, Brigittc Kunze. Gerhard Hofle, Hermann Augustiniak. Norbert Bedorf, RolfJansen, Wol- fram Trowitzseh-Kienast, Hcinrich Steinmetz, Wolfenb Federal Republic Of Germana as- signed to Ciba-Geigy Corporation; Gesellschaft fur giotechnologische Forschung m
The invention relates to novel polycyclic alkaloids of formula See Patent /or Chemical Structure (I) in which R I represents hydrogen or hydroxy, R2 represents hydrogen or acyl and A and B. independently of one another, each represents C double bondO or C-OH, and wherein the dashed line represents a C double bond(." double bond at the position of the middle bond when A or B represents C double bondO, or at the position of the two outer bonds when A or B represents (;-OH, a process for the manu- facture of these compounds by fermentation of a novel microorganism of the species Myxococcus xanthus, the novel microorganism itself, pharmacetical preparations that contain the novel compounds, and the use of the novel com- pounds as antibiotics and as turnout-inhibiting agents and for the manufacture of pharma- ceutical preparations.
5023243
O L I G O N U C L E O T I D E T H E R A P E U T I C A G E N T A N D
M E T H O D O F M A K I N G S A M E
Richard H Tullis assigned to Molecular Bio- systems Inc
For use in controlling biologic functions in an organism, a stabilized oligonucleotide, pre- ferably in a phosphotriester form, having a base sequence substantially complementary to a por- tion of messenger ribonucleic acid coding for a biological component, such as a protein, of the organism. The oligonucleotide has about four- teen bases or more, such as twenty-three bases, and can be a deoxyribonculeotide. The
5023320
P R O C E S S F O R T H E P U R I F I C A T I O N O F
P H Y S I O L O G I C A L L Y A C T I V E S U B S T A N C E H A V I N G
A N T I T U M O R A C T I V I T Y
Katsuyuk Haranaka, Lloyd J Old, Elizabeth Richards, Barbara Williamson. Knkubunji. NY. Japan assigned to Sloan-Kettering Institute For Cancer Research
A process is provided for the purification of a proteinaceous physiologically active substance having antitumor activity, which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloen- dothelial system and then injecting endotroxin from a Gram-negative bacterium into the rabbit. The process comprises contacting a crude solu- tion of said proteinaceous physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, eluting the adsorbed physiologically active substance, and subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight in the range of 30,000 to 70,000. The purified preparation of said physiologically ac- tive substance thus obtained may be used as an antitumore agent for the treatment of malignant tumors. Said physiologically active substance is isolated by subjecting the purified preparation successively to affinity chromatography on im- mobilized Cibarcron Blue F3G-A. gel filtration. affinity chromatography on immobilized con- canavalin A, preparative electrophoresis on polyacrylamide gel and gel filtration.
5034133
P U R I F I C A T I O N O F H U M A N I N T E R L E U K I N - 4 F R O M A CHO- CELl. L I N E C U L T U R E M E D I U M
David Naveh, Jay Raman, John C Tang, Leiden, N J, Netherlands assigned to Schering- Corporation
